Resveratrol in the management of human cancer: how strong is the clinical evidence? (Q38121595)

29 August 2017

Resveratrol in the management of human cancer: how strong is the clinical evidence? (English)

1 reference

29 August 2017

Andreas Gescher

1

1 reference

29 August 2017

William P Steward

series ordinal

2

1 reference

29 August 2017

Karen Brown

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 July 2013

1 reference

Annals of the New York Academy of Sciences

29 August 2017

1 reference

29 August 2017

1290

1 reference

29 August 2017

12-20

1 reference

Therapeutic potential of resveratrol: the in vivo evidence

29 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol and health--a comprehensive review of human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Clinical trials of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Cancer chemopreventive activity of resveratrol, a natural product derived from grapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol improves health and survival of mice on a high-calorie diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

What is new for an old molecule? Systematic review and recommendations on the use of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol in human cancer chemoprevention--choosing the 'right' dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Safety studies conducted on high-purity trans-resveratrol in experimental animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

The IGF axis and programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Insulin-like growth factor-I and cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

Resveratrol commonly displays hormesis: occurrence and biomedical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FNYAS.12205

21 January 2018

Identifiers

DOI

10.1111/NYAS.12205

1 reference

29 August 2017

1 reference